問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberN01358
Completed

2011-03-01 - 2012-06-30

Phase III

Terminated6

ICD-10G40.011

Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus

ICD-10G40.019

Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus

ICD-10G40.111

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus

ICD-10G40.119

Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus

ICD-9345.51

Partial epilepsy, without mention of impairment of consciousness, with intractable epilepsy

  • Trial Applicant

    Pharmaceutical Research Associates Taiwan Inc.

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator 蔡景仁 Division of Neurology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 姚俊興 Division of Neurology

Co-Principal Investigator

  • 陳倩 Division of Neurology

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 陳大成 Division of Neurology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 鄭天浚 Division of Neurology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator 謝福源 Division of Neurology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Principal Investigator Yu-Li Wu Division of Neurology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Terminated

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    38 participants

  • Global

    900 participants